Carrie Brodmerkel

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 789 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis

Thomas J. Richards, Naftali Kaminski, Fred Baribaud et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 393 citations · Full text

Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis

Mayte Suárez‐Fariñas, Katherine Li, Judilyn Fuentes‐Duculan et al. · Journal of Investigative Dermatology · 2012 · 302 citations · Full text

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Howard Sofen, Stacy Smith, Robert Matheson et al. · Journal of Allergy and Clinical Immunology · 2014 · 298 citations · Full text

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh, Christopher T. Ritchlin, Proton Rahman et al. · Annals of the Rheumatic Diseases · 2014 · 293 citations · Full text